Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Download your copy of the new events calendar and see all the online workshops, conferences, RAC exams and European online workshops RAPS has planned for 2021 at a glance.
Registration is now open for RAPS Euro Convergence 2021! Attend to join peers from EU and around the world to gain insights and exchange ideas on the regions most pressing issues.
An invaluable resource for any professional engaged in designing, composing, compiling, or commenting on regulatory documentation
From self-assessments to help you identify your strengths and areas to focus on to reference books and online courses that will help you fill in the gaps in your regulatory knowledge, RAPS has the resources to help you prepare for the RAC exam.
Posted 21 May 2012 | By Alexander Gaffney, RAC
The Pharmaceutical Research and Manufacturers of America (PhRMA) is calling for program proposed by the US Food and Drug Administration (FDA) to be scaled back, saying the agency's proposal to review all advertising before it can be disseminated is overly burdensome and violates its commercial rights to free speech.
FDA proposed on 12 March to change how it reviews TV advertisements-see Regulatory Focus' 12 March story, "New FDA Draft Guidance on DTC Television Advertisements"-releasing draft guidance to require all direct-to-consumer (DTC) TV advertisements to be reviewed by FDA before dissemination.
In its letter to FDA, published 14 May, PhRMA said while it "strongly supports" the policy goals advocated by FDA, the specific proposal "is, in important respects, overbroad, unduly burdensome, and lacking in narrow, objective and definitive standards."
PhRMA, a trade organization representing numerous companies, also cites the constitution in its letter.
The first amendment, argues PhRMA, confers protections to the commercial speech of companies, which are violated by FDA's proposed draft guidance.
"Because FDA is proposing to implement and enforce what is, in essence, a prior restraint on valuable constitutionally protected commercial speech, PhRMA urges the Agency to reconsider the scope of its proposal and proceed cautiously and in a manner that fully protects the free speech rights of advertisers and patients," wrote PhRMA.
Such limits should, if they exist at all, conform to the constitutional principle of being, as the Supreme Court upheld in Central Hudson, "narrowly tailored to serve a compelling state interest."
"PhRMA recommends that if FDA intends to pursue this effort, it should be implemented by means of notice and comment rulemaking in a tailored, risk-based approach that conforms with the Supreme Court's directive that "the First Amendment mandates that speech restrictions be narrowly drawn," PhRMA continued.
The group, which is the largest pharmaceutical trade body in the US, also argues current regulations give FDA adequate review time in which they can pull non-compliant regulations from circulation.
Finally, PhRMA argues FDA should-if at all-implement its proposed guidance through a formal rulemaking process rather than by issuing Guidance for Industry, as the current proposed guidance makes a substantive change to its regulatory practices.
Read more:
PhRMA - Pharmaceutical Research and Manufacturers of America (PhRMA) - Comment
Regulatory Focus - New FDA Draft Guidance on DTC Television Advertisements
Regulatory Focus - FDA Reopens Comment Period on DTC Advertising Regulations
Tags: Narrowly Tailored, Free Speech, First Amendment, DTC, PhRMA, Latest News, draft guidance, advertising, guidance
Regulatory Focus newsletters
All the biggest regulatory news and happenings.